Eastern Cooperative Oncology Group
A cooperative research group that designs and conducts multicenter, biomarker-driven oncology clinical trials across academic and community sites. The organization provides centralized research cores (imaging core, biorepository, sample tracking), centralized biostatistics and clinical data management, independent safety monitoring, investigator training and standardized patient-facing materials, and maintains network/site directories and trial web templates. Primary funding is from the National Cancer Institute and the group participates in national clinical trial networks (NCTN/NCORP).
Industries
Nr. of Employees
medium (51-250)
Eastern Cooperative Oncology Group
Philadelphia, Pennsylvania, United States, North America
Products
EA3191 — Head and neck cancer trial
Phase II/III clinical trial comparing adjuvant immunotherapy versus reirradiation plus platinum chemotherapy for high-risk recurrent or second primary head and neck squamous cell carcinoma; includes imaging and biomarker eligibility requirements and structured long-term follow-up.
EA3161 — Definitive therapy followed by PD-1 inhibitor trial (throat cancer)
Randomized trial comparing definitive concurrent chemoradiation followed by a PD-1 immune checkpoint inhibitor versus chemoradiation followed by observation, with crossover option on progression; includes integrated imaging and biomarker substudies and protocol-specified radiotherapy planning.
EAQ211 — Observational social and genetic factors study in AYA survivors
Observational study investigating social-environmental and genetic contributors to outcomes in adolescent and young adult survivors of Hodgkin or non-Hodgkin lymphoma or leukemia; collects blood samples, questionnaires on quality of life, and longitudinal follow-up to link social factors and gene expression to outcomes.
EA3191 — Head and neck cancer trial
Phase II/III clinical trial comparing adjuvant immunotherapy versus reirradiation plus platinum chemotherapy for high-risk recurrent or second primary head and neck squamous cell carcinoma; includes imaging and biomarker eligibility requirements and structured long-term follow-up.
EA3161 — Definitive therapy followed by PD-1 inhibitor trial (throat cancer)
Randomized trial comparing definitive concurrent chemoradiation followed by a PD-1 immune checkpoint inhibitor versus chemoradiation followed by observation, with crossover option on progression; includes integrated imaging and biomarker substudies and protocol-specified radiotherapy planning.
EAQ211 — Observational social and genetic factors study in AYA survivors
Observational study investigating social-environmental and genetic contributors to outcomes in adolescent and young adult survivors of Hodgkin or non-Hodgkin lymphoma or leukemia; collects blood samples, questionnaires on quality of life, and longitudinal follow-up to link social factors and gene expression to outcomes.
Services
Design, implementation, and operational support for randomized and non-randomized clinical trials across a national and international site network; includes protocol development, site activation, monitoring, and long-term follow-up processes.
Centralized imaging laboratory services (imaging collection and central review), specimen storage and pathology review, and sample tracking systems to support correlative and translational research.
Statistical design, interim and final analyses, and centralized trial data management and reporting services.
Development and delivery of investigator training programs, mentorship activities, and production of standardized investigator- and patient-facing educational and recruitment templates to support site readiness and enrollment.
Creation and publication of standardized trial page templates (active, pre-NCI, closed) including patient-friendly trial summaries, educational/recruitment links, press release placement, and links to official registry records.
Maintenance of member resources, FAQs, investigator contact tools, and searchable participating-institution listings to support member and site needs.
Design, implementation, and operational support for randomized and non-randomized clinical trials across a national and international site network; includes protocol development, site activation, monitoring, and long-term follow-up processes.
Centralized imaging laboratory services (imaging collection and central review), specimen storage and pathology review, and sample tracking systems to support correlative and translational research.
Statistical design, interim and final analyses, and centralized trial data management and reporting services.
Development and delivery of investigator training programs, mentorship activities, and production of standardized investigator- and patient-facing educational and recruitment templates to support site readiness and enrollment.
Creation and publication of standardized trial page templates (active, pre-NCI, closed) including patient-friendly trial summaries, educational/recruitment links, press release placement, and links to official registry records.
Maintenance of member resources, FAQs, investigator contact tools, and searchable participating-institution listings to support member and site needs.
Expertise Areas
- Clinical trial management
- Biomarker-driven translational research
- Imaging-based response assessment
- Biostatistics and centralized clinical data management
Key Technologies
- FDG-PET/CT imaging
- CT and MRI imaging
- PET-based response criteria
- RECIST 1.1 tumor response criteria
News & Updates
Press release reporting results from the randomized phase 3 EA4151 trial showing no overall survival benefit from consolidative autologous stem cell transplant in mantle cell lymphoma patients with undetectable minimal residual disease.
Summary of ECOG-ACRIN-affiliated presentations at the San Antonio Breast Cancer Symposium, including imaging response studies and multimodal AI research.
Official NCI clinical trial record summarizing objectives, eligibility, imaging and biomarker endpoints, treatment arms including adjuvant PD-1 inhibitor versus observation, and follow-up schedule.
Interim analysis from the EA4151 phase 3 trial led by the group showed similar 3-year overall survival for patients receiving autologous stem cell transplant plus maintenance therapy versus maintenance therapy alone, prompting early stopping of accrual.
Press release reporting results from the randomized phase 3 EA4151 trial showing no overall survival benefit from consolidative autologous stem cell transplant in mantle cell lymphoma patients with undetectable minimal residual disease.
Summary of ECOG-ACRIN-affiliated presentations at the San Antonio Breast Cancer Symposium, including imaging response studies and multimodal AI research.
Official NCI clinical trial record summarizing objectives, eligibility, imaging and biomarker endpoints, treatment arms including adjuvant PD-1 inhibitor versus observation, and follow-up schedule.
Interim analysis from the EA4151 phase 3 trial led by the group showed similar 3-year overall survival for patients receiving autologous stem cell transplant plus maintenance therapy versus maintenance therapy alone, prompting early stopping of accrual.